Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Savani
Bipin N
BN
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10, Hatfield CRC, Room 3-5330, 10 Center Drive MSC 1202, Bethesda, MD 20892-1202, USA.
Srinivasan
Ramaprasad
R
Espinoza-Delgado
Igor
I
Dorrance
Colleen
C
Takahashi
Yoshiyuki
Y
Igarashi
Takehito
T
Rezvani
Katayoun
K
Lundqvist
Andreas
A
Barrett
A John
AJ
Childs
Richard W
RW
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate